Moderna's cancer vaccine trials may change treatment

Moderna and Merck announced successful results from a Phase 3 trial of a personalized mRNA melanoma vaccine, called intismeran, used alongside Keytruda to prevent cancer recurrence and spread. The therapy, tailored to each patient's genetic tumor profile, extended survival and reduced the risk of relapse, signaling a potential breakthrough in cancer treatment. Moderna plans to seek FDA approval and is testing similar vaccines for other cancers, leveraging its rapid, personalized manufacturing process developed during the COVID pandemic.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل